[Systemic sclerosis: Efficacy of intravenous immunoglobulins in severe cardiac involvement?]

Rev Med Interne. 2018 Jul;39(7):594-596. doi: 10.1016/j.revmed.2017.12.013. Epub 2018 Feb 4.
[Article in French]

Abstract

Background: The heart involvement in systemic sclerosis is frequent and can touch various sites. The prognosis in the presence of heart disease is poor, but few data are available about its management.

Case: We report the case of 48 years old woman with systemic sclerosis which presented severe heart involvement. She has severe heart failure, supraventricular arrhythmias and symptomatic pericarditis, which required surgical intervention and immunosuppressive drugs (steroids with rituximab). Despite this treatment, she has persistent severe heart impaired function and intravenous immunoglobulins have been initiated. She experienced progressively the improvement of dyspnea, of heart systolic ejection fraction and decrease of Rodnan scale.

Conclusion: Our case illustrates a severe heart involvement in systemic sclerosis which have been improved by intravenous immunoglobulins.

Keywords: Atteinte cardiaque; Heart involvement; Immunoglobulines intraveineuses; Intravenous immunoglobulins; Sclérodermie systémique; Systemic sclerosis.

Publication types

  • Case Reports

MeSH terms

  • Arrhythmias, Cardiac / drug therapy*
  • Arrhythmias, Cardiac / etiology
  • Female
  • Heart Failure / drug therapy*
  • Heart Failure / etiology
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Middle Aged
  • Scleroderma, Systemic / complications
  • Scleroderma, Systemic / drug therapy*
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Immunoglobulins, Intravenous